Figure 1 Comparison of baseline features: Limited vs Diffuse SSc. (A) 158 patients with SSc, symptomatic restrictive lung disease, and evidence of active alveolitis on either BAL (neutrophilia >3% and/or eosinophilia >2%) and/or HRCT (presence of any ground‐glass opacity) were randomised to the SLS with the breakdown of limited and diffuse SSc, and their findings on BAL and HRCT as shown. (B) Differences between limited and diffuse patients with respect to baseline measures of pulmonary function (FVC, TLC, DLCO), represented as a percentage of predicted normal values; specific components of health related quality of life (Breathing Symptoms Visual Analog Scale (Breathing) and Patient's Global Assessment Visual Analog Scale (PGA) of the Scleroderma Health Assessment Questionnaire), on a 0–100 scale where higher values indicate worse symptoms; and total score for lung fibrosis by HRCT (Fibrosis Score) and modified Rodnan Skin Score (Skin Score), where a higher score indicates more extensive findings. Values represent mean±SE for each group. *p<0.0002 comparing lcSSc with dcSSc.